Dr. Jean-Claude Tardif Receives the Prestigious Margolese National Heart Disorders Prize
Home > Press room > Dr. Jean-Claude Tardif Receives the Prestigious Margolese National Heart Disorders PrizeSeptember 15, 2021
─
The Montreal Heart Institute (MHI) is proud to announce that Dr. Jean-Claude Tardif has been honoured with the 2021 Margolese National Heart Disorders Prize.
This prestigious distinction is awarded annually to a Canadian physician or scientist who makes outstanding contributions to heart disorders’ treatment, amelioration, or cure.
A leading researcher at the Institute
Dr. Tardif is one of the most gifted cardiology researchers of his time. Director of the MHI Research Centre and Professor of Medicine at the Université de Montréal (UdeM), he has received numerous national and international distinctions for his work, including the Order of Canada, the country’s highest honour.
His research focuses on the pathophysiology and treatment of atherosclerosis using precision medicine, pharmacogenomics, advanced molecular approaches, innovative imaging, and randomized clinical trials to tackle relevant and vital questions.
find out more by visiting the Institute’s website
Press Room
December 6, 2023The Right Honourable Brian Mulroney and Mrs. Mila Mulroney donate $1.5 million to support the foundations of two hospitals and a research institute
October 31, 2023Céline Auger, Dominique Morency-Laflamme, and Isabelle Gauthier named recipients of the 2023 Dr. Denis Roy Awards for Excellence in Cardiovascular Care
September 8, 202323rd edition of the Grand Bal des Vins-Cœurs: $1,380,000 raised for the Montreal Heart Institute Foundation
You will also like:
Health Canada approval of low-dose colchicine for cardiovascular disease based on the COLCOT study
People with coronary disease now have a new treatment option to reduce the risk of cardiovascular events. Health Canada has issued a Notice of Compliance for the prescription drug MYINFLA™ (colchicine 0.5 mg tablets) based on the results of the Montreal Heart Institute (MHI)’s COLCOT clinical trial.
Read more →
The Department of Surgery implants a new biological aortic prosthesis
The Montreal Heart Institute announces that the surgery department has implanted a new biological aortic prosthesis in a patient, a Canadian first. This cutting-edge medical device reduces the time required for surgery and the risk of complications; thus, patients enjoy a better quality of life.
Read more →
The COLCOT study: a world-class discovery made at the Montreal Heart Institute
Researchers at the Montreal Heart Institute launched a global study titled COLCOT (COLchicine Cardiovascular Outcomes Trial) in 2014. The goal was to determine whether colchicine, a widely available drug, could prevent the risk of heart attacks in patients who had already experienced this kind of event.
Read more →